FALNIDAMOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H19ClFN7
Molecular Weight	387.842
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCC(CC1)NC2=NC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=N2

InChI

InChIKey=FTFRZXFNZVCRSK-UHFFFAOYSA-N

InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)

HIDE SMILES / InChI

Molecular Formula	C18H19ClFN7
Molecular Weight	387.842
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12008195

Falnidamol is an epidermal growth factor receptor inhibitor, developed by Boehringer Ingelheim. Falnidamol demonstrated anticancer activity in vitro. The phase I trial was discontinued due to a dose-limiting increase of liver enzymes, low bioavailability of the drug and the detection of a pharmacologically inactive metabolite.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Epidermal growth factor receptor 46 Target ID: P00533\|\|\|Q9GZX1 Gene ID: 1956.0 Gene Symbol: EGFR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12008195	Inhibitor 8297		3.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12008195	Primary		Phase I 428	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
		substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461	AO 16

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1650	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=377020239	inconclusive [IC50 25.929 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12008195/	major
AO 16	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12008195/	yes

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00ABZS	https://www.1pchem.com/search?query=1P00ABZS
AChemBlock	10233	http://www.achemblock.com/catalogsearch/result/?q=10233
AK Scientific	SYN5568	https://aksci.com/item_detail.php?cat=SYN5568
AOBIOUS INC	AOB5489	http://aobious.com/aobious/search?search_query=AOB5489
Angene	AGN-PC-0WHA07	http://www.angenechemical.com/productshow/AGN-PC-0WHA07.html
ApexBio Technology	A3240	https://www.apexbt.com/catalogsearch/result/?q=A3240
AstaTech	40762	http://astatechinc.com/CPSResult.php?CRNO=40762
BLD Pharm	BD303668	http://www.bldpharm.com/search/Search.html?keyword=BD303668
BOC Sciences	196612-93-8	http://www.bocsci.com/description.asp?cas=196612-93-8
Chem Scene	CS-0691	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0691
ChemShuttle	134406	https://www.chemshuttle.com/catalogsearch/result/?q=134406
Debye Scientific	DB-014915	https://www.debyesci.com/index.php?id=product&ext[cno]=DB-014915
Excenen	EX-A570	http://www.excenen.com/searchresultlist.php?id=EX-A570
Exclusive Chemistry	2387	http://www.exchemistry.com/chem-catalog/product-2387.html
KeyOrganics	AS-16894	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16894
Lab Network	LN01299307	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01299307
Matrix Scientific	153988	http://www.matrixscientific.com/153988.html
MedChem Express	HY-10322	https://www.medchemexpress.com/search.html?q=HY-10322&ft=&fa=&fp=
MolPort	MolPort-021-783-059	https://www.molport.com/shop/molecule-link/MolPort-021-783-059
MolPort	MolPort-039-136-623	https://www.molport.com/shop/molecule-link/MolPort-039-136-623
MuseChem	I010550	https://www.musechem.com/product/I010550.html
ShangHai Biochempartner	BCP001133	http://www.biochempartner.com/search_BCP001133
ShangHai Biochempartner	BCP09515	http://www.biochempartner.com/search_BCP09515
Tocris	2416	https://www.tocris.com/search.php?Type=QuickSearch&Value=2416
Wonderchem	WD05IQU	http://www.wonder-chem.com/search.html?text=WD05IQU
eMolecules	17400145	https://orderbb.emolecules.com/search/#?query=17400145
eMolecules	300117866	https://orderbb.emolecules.com/search/#?query=300117866
eMolecules	44811572	https://orderbb.emolecules.com/search/#?query=44811572
mcule	MCULE-6165916754	https://mcule.com/MCULE-6165916754/

PubMed

Title	Date	PubMed
In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.	2000 Jan 25	10692650
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.	2002 May	12008195
Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.	2004 Nov	15199094

Patents

Sample Use Guides

In Vivo Use Guide

In a phase I study, patients received falnidamol orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 150 mg.

Route of Administration: Oral

In Vitro Use Guide

T47D cells were treated with falnidamol at 0.01, 0.03, 0.1, 0.3, 1, 3, 10 uM for 1 h. 3 uM of the drug was sufficient to block signaling by TGF-alpha. 10 uM falnidamol blocked ErbB2 activity efficiently.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:17:42 GMT 2023` Edited by `admin` on `Fri Dec 15 16:17:42 GMT 2023`
Record UNII	0MU316797D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FALNIDAMOL

Official Name

English

BIBX1382

Common Name

English

Falnidamol [WHO-DD]

Common Name

English

8-(3-CHLORO-4-FLUOROANILINO)-2-((1-METHYL-4-PIPERIDYL)AMINO)PYRIMIDO(5,4-D)PYRIMIDINE

Systematic Name

English

BIBX-1382

Code

English

falnidamol [INN]

Common Name

English

BIBX 1382

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C2167